Literature DB >> 10384102

Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.

I F Hermans1, D S Ritchie, A Daish, J Yang, M R Kehry, F Ronchese.   

Abstract

The contribution of CD4+ T cells to dendritic cell (DC) activation and to the induction of CD8+ T cell responses in vivo was investigated using a model of antitumor immune responses. Immunization with peptide-loaded MHC class II-deficient (MHC class II-/-) DC induced the activation of Ag-specific CD8+ T cells and their accumulation in the lymph nodes and spleens of immunized mice. The accumulation induced by MHC class II-/- DC immunization was lower than the accumulation observed after immunization with MHC class II+/+ DC. Similarly, immunization with peptide-loaded, MHC class II-/- DC induced some degree of protection against tumor challenge, but this protection was lower than the protection achieved after immunization with MHC class II+/+ DC. Incubation with a membrane-associated form of CD40 ligand resulted in the up-regulation of costimulatory molecules on MHC class II-/- DC and fully rescued their ability to induce antitumor immunity. We conclude that CD4+ T cells play a critical role in the generation of antitumor immune responses through their capacity to induce the activation of DC via CD40/CD40 ligand interaction, and thus maximize CD8+ T cell responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin.

Authors:  S Jolles; J Christensen; M Holman; G B Klaus; A Ager
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  Immunoregulation of dendritic cells.

Authors:  Mark A Wallet; Pradip Sen; Roland Tisch
Journal:  Clin Med Res       Date:  2005-08

3.  CD40 engagement on dendritic cells, but not on B or T cells, is required for long-term control of murine gammaherpesvirus 68.

Authors:  Francesca Giannoni; Ashley Shea; Chandra Inglis; Lian Ni Lee; Sally R Sarawar
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

4.  Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells.

Authors:  Brenda Faiola; Carolyn Doyle; Eli Gilboa; Smita Nair
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

5.  CD4⁺ and CD8⁺ T cell-dependent antiviral immunity requires STIM1 and STIM2.

Authors:  Patrick J Shaw; Carl Weidinger; Martin Vaeth; Kevin Luethy; Susan M Kaech; Stefan Feske
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

Review 6.  Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity.

Authors:  Mario A Ostrowski; Qigui Yu; Feng Yun Yue; Jun Liu; Brad Jones; Xiao X Gu; Mona Loutfy; Colin M Kovacs; Roberta Halpenny
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  SHARPIN is essential for cytokine production, NF-κB signaling, and induction of Th1 differentiation by dendritic cells.

Authors:  Zhe Wang; Anna Sokolovska; Rosemarie Seymour; John P Sundberg; Harm Hogenesch
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

Review 8.  CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies.

Authors:  Timothy N J Bullock
Journal:  Cell Mol Immunol       Date:  2021-07-19       Impact factor: 11.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.